文献速递糖尿病肥胖与代谢综合征骨质疏松与钙磷/甲状旁腺

肥胖男性合并2型糖尿病与骨小梁微结构及骨强度变差相关

In Men With Obesity, T2DM Is Associated With Poor Trabecular Microarchitecture and Bone Strength and Low Bone Turnover.
PubMed 文献 · J Clin Endocrinol Metab · 2021-01-01

该研究纳入112名肥胖男性,比较代谢健康肥胖(MHO)、不伴2型糖尿病的代谢不健康肥胖(MUHO)及伴2型糖尿病的MUHO三组之间的骨转换指标、骨密度、骨微结构与骨强度。结果显示,肥胖合并2型糖尿病者骨转换降低,胫骨与桡骨骨小梁分离度增大,胫骨失效载荷与刚度下降。

要点

  • 肥胖男性合并2型糖尿病时骨转换水平更低,提示骨代谢受抑。
  • 合并2型糖尿病者胫骨与桡骨骨小梁分离度更大,骨小梁微结构更差。
  • 胫骨失效载荷与刚度降低,提示骨强度下降,骨折风险可能更高。

核心结论

  • 在男性中,肥胖合并2型糖尿病与骨转换降低、骨小梁微结构变差及骨强度下降相关,提示骨病更严重。

研究设计与样本

  • 研究纳入112名肥胖男性的数据。
  • 骨转换与生化标志物采用酶联免疫吸附测定,体成分与各部位骨密度采用双能X线吸收法评估。
  • 骨微结构与骨强度(刚度与失效载荷)采用高分辨率外周定量CT测量。
  • 数据在代谢健康肥胖(MHO)、不伴2型糖尿病的代谢不健康肥胖(MUHO)及伴2型糖尿病的MUHO之间比较,并在伴与不伴2型糖尿病的肥胖者之间比较。

主要发现

  • 与不伴2型糖尿病的MHO和MUHO相比,伴2型糖尿病的MUHO骨钙素水平显著更低(分别为7.49 ± 3.0与6.03 ± 2.47 vs 4.24 ± 2.72 ng/mL,P = 0.003)。
  • 与不伴2型糖尿病的MHO和MUHO相比,伴2型糖尿病的MUHO I型胶原C端肽(CTx)水平显著更低(分别为0.28 ± 0.10与0.29 ± 0.13 vs 0.21 ± 0.15 ng/mL,P = 0.02)。
  • 按是否合并2型糖尿病二分后,伴2型糖尿病的肥胖男性骨钙素(P = 0.003)与CTx(P = 0.005)显著更低。
  • 伴2型糖尿病的肥胖男性胫骨与桡骨骨小梁分离度更大(分别为P = 0.03与P = 0.04),胫骨失效载荷与刚度均更低(均P = 0.04)。

临床怎么用

  • 对肥胖男性评估骨健康时,合并2型糖尿病者应关注骨转换降低与骨小梁微结构变差。
  • 此类患者骨密度可能不低,但骨强度下降,骨折风险评估不宜仅依赖骨密度。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Obesity and type 2 Diabetes (T2D) are both associated with greater bone mineral density (BMD) but increased risk of fractures. The effect of the combination of both conditions on bone metabolism, microarchitecture, and strength in the obese population remains unknown. METHODS: Data from 112 obese men were collected. Bone turnover and biochemical markers were measured by enzyme-linked immunosorbent assay, body composition and BMD at all sites were assessed by dual energy X-ray absorptiometry, whereas bone microarchitecture and strength (stiffness and failure load) were measured by high-resolution peripheral computed tomography. Data were compared among metabolically healthy obese (MHO) and metabolically unhealthy obese (MUHO) with and without T2D and between obese without and with T2D. RESULTS: Compared to MHO and MUHO without T2D, MUHO with T2D had significantly lower levels of osteocalcin ((7.49 ± 3.0 and 6.03 ± 2.47 vs 4.24 ± 2.72 ng/mL, respectively, P = 0.003) and C-terminal telopeptide of type I collagen (CTx) (0.28 ± 0.10 and 0.29 ± 0.13 vs 0.21 ± 0.15 ng/mL, respectively, P = 0.02). Dividing our subjects simply into those with and without T2D showed that obese men with T2D had significantly lower levels of osteocalcin (P = 0.003) and CTx (P = 0.005), greater trabecular separation at the tibia and radius (P = 0.03 and P = 0.04, respectively), and lower tibial failure load and stiffness (both P = 0.04), relative to obese men without T2D. CONCLUSION: In men, the combination of obesity and T2D is associated with reduced bone turnover and poorer trabecular bone microarchitecture and bone strength compared to those who are obese but without T2D, suggesting worse bone disease.

来源:J Clin Endocrinol Metab,查看原文。版权归原作者所有。

引用

  1. Vigevano F, Gregori G, Colleluori G, et al. In Men With Obesity, T2DM Is Associated With Poor Trabecular Microarchitecture and Bone Strength and Low Bone Turnover. J Clin Endocrinol Metab. 2021. PMID: 33537757. doi:10.1210/clinem/dgab061

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。